Inventor · disambiguated record
Ofer Mandelboim
Also filed as: MANDELBOIM OFER
9 granted patents·10 pending applications·10 citations·filing 2001–2024
80Inventor score
Files withYISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD11YISSUM RES DEV CO3MANDELBOIM OFER2NATSPEARS LTD1NECTIN THERAPEUTICS LTD1
Top patents by PatentIndex Score
19 records- 0178US8980244B2Method of treating type 1 diabetes by administering NKp46 polypeptideYISSUM RES DEV CO·Filed 2013·Granted Mar 17, 2015·3 cites·18 claims
- 0275US2024018257A1Antibodies specific to human poliovirus receptor (pvr)YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD·Filed 2023·Application pending·0 cites
- 0374US10716864B2Anti-NKP46 antibodies, toxin conjugates, and therapeutic use of sameYISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD·Filed 2018·Granted Jul 21, 2020·2 cites·37 claims
- 0471US7825085B2Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cellsYISSUM RES DEV CO·Filed 2004·Granted Nov 2, 2010·4 cites·26 claims
- 0568US10946095B2Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD·Filed 2016·Granted Mar 16, 2021·1 cites·13 claims
- 0667US2024376202A1Antibodies specific to human nectin4YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD·Filed 2024·Application pending·0 cites
- 0766US2010047169A1NK Cell Receptor Conjugates for Treating MalignanciesNATSPEARS LTD·Filed 2009·Application pending·0 cites
- 0864US2021115150A1Antibodies specific to human poliovirus receptor (pvr)YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD·Filed 2020·Application pending·0 cites
- 0962US12121579B2Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT)YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD·Filed 2021·Granted Oct 22, 2024·0 cites·16 claims
- 1057US12077583B2Antibodies specific to human NECTIN4YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD·Filed 2019·Granted Sep 3, 2024·0 cites·13 claims
- 1157US10906987B2Antibodies specific to human poliovirus receptor (PVR)YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD·Filed 2017·Granted Feb 2, 2021·0 cites·11 claims
- 1251US2007280938A1Peptides Derived from Natural Cytotoxicity Receptors and Methods of Use ThereofYISSUM RES DEV CO·Filed 2004·Application pending·0 cites
- 1349US2006165592A1Nk cell receptor conjugates for treating malignanciesMANDELBOIM OFER·Filed 2003·Application pending·0 cites
- 1447US8420092B2Method of treating diabetes by administering an anti-NKp46 antibodyMANDELBOIM OFER·Filed 2010·Granted Apr 16, 2013·0 cites·10 claims
- 1547US2023183342A1Antibodies to nkp46 and constructs thereof for treatment of cancers and infectionsYISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD·Filed 2021·Application pending·0 cites
- 1642US10918677B2Attenuated or inactivated pathogenic Escherichia coli for treating urogenital cancerYISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD·Filed 2015·Granted Feb 16, 2021·0 cites·11 claims
- 1742US2024270840A1Antibodies against cd112r and uses thereofNECTIN THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1835US2004072256A1Nk cells activiating receptors and their therapeutic and diagnostic usesFiled 2001·Application pending·0 cites
- 1932US2018028601A1Methods and compositions for treating cancerYISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ofer Mandelboim files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →